Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Richard A, Koup"'
Autor:
Cynthia L Gay, Katherine S James, Marina Tuyishime, Shane D Falcinelli, Sarah B Joseph, Matthew J Moeser, Brigitte Allard, Jennifer L Kirchherr, Matthew Clohosey, Samuel L M Raines, David C Montefiori, Xiaoying Shen, Robert J Gorelick, Lucio Gama, Adrian B McDermott, Richard A Koup, John R Mascola, Michelle Floris-Moore, JoAnn D Kuruc, Guido Ferrari, Joseph J Eron, Nancie M Archin, David M Margolis
Publikováno v:
J Infect Dis
We tested the combination of a broadly neutralizing HIV antibody with the latency reversal agent vorinostat (VOR). Eight participants received 2 month-long cycles of VRC07-523LS with VOR. Low-level viremia, resting CD4+ T-cell–associated HIV RNA (r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6faf11d8516c4ae68e516f570f2bdba2
https://europepmc.org/articles/PMC8889279/
https://europepmc.org/articles/PMC8889279/
Autor:
Michele P. Andrasik, Weiping Deng, Yiwen Lu, Bob C. Lin, Ruben O. Donis, Youyi Fong, Mira Baron, Lindsay N. Carpp, Lars W. P. van der Laan, Immune Assays Team, Adrian B. McDermott, Karen Martins, Lindsey R. Baden, Flora Castellino, James G. Kublin, Luis De La Cruz, Honghong Zhou, Chuong Huynh, Rolando Pajon, Amanda Eaton, David Benkeser, Mark Kutner, Dean Follmann, Marcella Sarzotti-Kelsoe, CoVPN Biostatistics Team, Hana M. El Sahly, Charlene McDanal, Jacqueline Miller, Christopher R. Houchens, Nima S. Hejazi, Kathleen M. Neuzil, Spyros A. Kalams, Bhavesh Borate, Coronavirus Efficacy (Cove) Team, David C. Montefiori, Lakshmi Jayashankar, Colleen F. Kelley, Richard A. Koup, Britta Flach, Peter B. Gilbert, Lawrence Corey, Chenchen Yu
Publikováno v:
medRxiv
article-version (status) pre
article-version (number) 4
article-version (status) pre
article-version (number) 4
BackgroundIn the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and as correlates of protection.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ffccfeae7ead57a33edd54278a0c324
https://doi.org/10.1101/2021.08.09.21261290
https://doi.org/10.1101/2021.08.09.21261290
Autor:
Eirini Moysi, Perla M. Del Rio Estrada, Fernanda Torres-Ruiz, Gustavo Reyes-Terán, Richard A. Koup, Constantinos Petrovas
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
CD4 T cells are key mediators of adaptive immune responses during infection and vaccination. Within secondary lymphoid organs, helper CD4 T cells, particularly those residing in germinal centers known as follicular helper T cells (Tfh), provide criti
Autor:
Constantinos Petrovas, Giulia Fabozzi, Rafick-Pierre Sekaly, Alessandra Noto, Maria Maddalena Perra, Craig Fenwick, Giuseppe Pantaleo, Sanjana Shah, Alexander Chassiakos, Vasilis Papaioannou, Richard A. Koup, Daniel C. Douek, Kartika Padhan, David R. Ambrozak, Khader Ghneim, Eirini Moysi, Antigoni Poultsidi, Samuel Darko, Maria Ioannou
Publikováno v:
Proc Natl Acad Sci U S A
The development of follicular helper CD4 T (TFH) cells is a dynamic process resulting in a heterogenous pool of TFH subsets. However, the cellular and molecular determinants of this heterogeneity and the possible mechanistic links between them is not
Autor:
Michael Chambers, Safiatou Doumbo, Sarah F. Andrews, Peter D. Crompton, Peter D. Sun, Eric O. Long, Shanping Li, Mary E. Peterson, Richard A. Koup, Boubacar Traore, Kristin L. Boswell, Adrian B. McDermott, Joshua Tan, Aissata Ongoiba, Kassoum Kayentao, Jinghua Lu, Kazutoyo Miura, Christopher M. Tipton, Ababacar Diouf, Carole A. Long, Padmapriya Sekar, Christine S. Hopp, Silvia Portugal, Jeff Skinner
Publikováno v:
The Journal of Experimental Medicine
The role of IgM in human malaria is unclear. In a cohort study in Mali, Hopp et al. find that malaria-specific memory B cells are disproportionally IgM in children, are activated during acute malaria, and produce IgM that inhibits malaria parasite gr
Publikováno v:
Methods. 154:118-124
Bispecific (bs) antibodies (Abs, bsAbs) are engineered immunoglobulins that contain two different antigen-binding sites in one molecule. bsAbs can be divided in two molecular formats; the IgG-like and non-IgG like. The structural elements of each for
Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses
Autor:
Rebecca A. Gillespie, Peter D. Kwong, Julie E. Ledgerwood, John R. Gallagher, Richard A. Koup, Madhu Prabhakaran, Brian E. Fisher, David R. Ambrozak, John R. Mascola, Ulrich Baxa, Masaru Kanekiyo, Barney S. Graham, Wing-Pui Kong, M. Gordon Joyce, Kathryn L Zephir, Adrian B. McDermott, Sarah F. Andrews, Hanne Andersen, Adrian Creanga, Adam K. Wheatley, Audray K. Harris, Kwanyee Leung, Ivelin S. Georgiev, Eun Sung Yang, Seyhan Boyoglu-Barnum, Yaroslav Tsybovsky, Hadi M. Yassine
Publikováno v:
Nature immunology
The present vaccine against influenza virus has the inevitable risk of antigenic discordance between the vaccine and the circulating strains, which diminishes vaccine efficacy. This necessitates new approaches that provide broader protection against
Publikováno v:
Retrovirology, Vol 15, Iss 1, Pp 1-10 (2018)
Retrovirology
Retrovirology
The induction of HIV-1-specific antibodies that can neutralize a broad number of isolates is a major goal of HIV-1 vaccination strategies. However, to date no candidate HIV-1 vaccine has successfully elicited broadly neutralizing antibodies of suffic
Autor:
Jason Hataye, Zhi Yong Yang, Nicole A. Doria-Rose, John R. Mascola, Giulia Fabozzi, Hui Li, Tongqing Zhou, Wei Shi, Kylie March, Brandon F. Keele, George M. Shaw, Joseph P. Casazza, Kathryn E. Foulds, Joana Dias, Wanwisa Promsote, Gary J. Nabel, Michelle D. Cully, Richard A. Koup, Xuejun Chen, Amarendra Pegu, Ling Xu, Ronnie Wei, Hui Geng, Cuiping Liu, Amy Noe, Jeffrey D. Lifson, Cassandra G. Almasri, Ercole Rao, Constantinos Petrovas, Mangaiarkarasi Asokan, John-Paul Todd, Krisha McKee, Christine M. Fennessey, Stephen D. Schmidt, Eun Sung Yang, Megan E. DeMouth, Keyun Wang, Shing-Fen Kao
Publikováno v:
SSRN Electronic Journal.
Broadly neutralizing antibodies (bNAbs) represent an alternative to drug therapy for the treatment of HIV-1 infection. Immunotherapy with single bNAbs often leads to emergence of escape variants, suggesting a potential benefit of combination bNAb the
Autor:
Laura L. Sutherland, Takuya Yamamoto, Barton F. Haynes, Norman L. Letvin, Madhu Prabhakaran, Wesley Hoyland, Sandeep Narpala, David J. Pickup, Steven Ma, Christopher Fletez-Brant, Mario Roederer, Sampa Santra, Adrian B. McDermott, Hua-Xin Liao, Richard A. Koup, Michelle L. Lifton, Elizabeth Ramsburg, Kristin L. Boswell, Gail Levine, Constantinos Petrovas, Leila Eslamizar, David J. Leggat, Kathryn Furr, David C. Montefiori
Publikováno v:
NPJ Vaccines
npj Vaccines, Vol 6, Iss 1, Pp 1-10 (2021)
npj Vaccines, Vol 6, Iss 1, Pp 1-10 (2021)
The RV144 HIV-1 vaccine trial has been the only clinical trial to date that has shown any degree of efficacy and associated with the presence of vaccine-elicited HIV-1 envelope-specific binding antibody and CD4+ T-cell responses. This trial also show